These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35970588)

  • 1. Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease.
    Macklin EA; Coffey CS; Brumm MC; Seibyl JP
    Neurology; 2022 Aug; 99(7 Suppl 1):68-75. PubMed ID: 35970588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifestyle Interventions for the Prevention of Parkinson Disease: A Recipe for Action.
    Janssen Daalen JM; Schootemeijer S; Richard E; Darweesh SKL; Bloem BR
    Neurology; 2022 Aug; 99(7 Suppl 1):42-51. PubMed ID: 35970584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.
    Meles SK; Oertel WH; Leenders KL
    Mol Med; 2021 Sep; 27(1):111. PubMed ID: 34530732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
    Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts.
    Molsberry SA; Hughes KC; Schwarzschild MA; Ascherio A
    Neurology; 2022 Aug; 99(7 Suppl 1):26-33. PubMed ID: 35970591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study.
    Fereshtehnejad SM; Yao C; Pelletier A; Montplaisir JY; Gagnon JF; Postuma RB
    Brain; 2019 Jul; 142(7):2051-2067. PubMed ID: 31111143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive changes in prodromal Parkinson's disease: A review.
    Fengler S; Liepelt-Scarfone I; Brockmann K; Schäffer E; Berg D; Kalbe E
    Mov Disord; 2017 Dec; 32(12):1655-1666. PubMed ID: 28980730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognition in prodromal Parkinson's disease.
    Liepelt-Scarfone I; Ophey A; Kalbe E
    Prog Brain Res; 2022; 269(1):93-111. PubMed ID: 35248208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.
    Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    JAMA Neurol; 2017 Aug; 74(8):933-940. PubMed ID: 28595287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prodromal Parkinson's disease: hype or hope for disease-modification trials?
    Mahlknecht P; Marini K; Werkmann M; Poewe W; Seppi K
    Transl Neurodegener; 2022 Feb; 11(1):11. PubMed ID: 35184752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in Prodromal Parkinson Disease: a Qualitative Review.
    Cooper CA; Chahine LM
    J Int Neuropsychol Soc; 2016 Nov; 22(10):956-967. PubMed ID: 27903331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prodromal PD: A new nosological entity.
    Schaeffer E; Postuma RB; Berg D
    Prog Brain Res; 2020; 252():331-356. PubMed ID: 32247370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodromal Parkinson disease in patients with idiopathic hyposmia.
    Marrero-González P; Iranzo A; Bedoya D; Serradell M; Niñerola-Baizán A; Perissinotti A; Gaig C; Vilaseca I; Alobid I; Santamaría J; Mullol J
    J Neurol; 2020 Dec; 267(12):3673-3682. PubMed ID: 32676768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome Assessment in Parkinson Disease Prevention Trials: Utility of Clinical and Digital Measures.
    Mirelman A; Siderowf A; Chahine L
    Neurology; 2022 Aug; 99(7 Suppl 1):52-60. PubMed ID: 35970590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease.
    de Aquino CH
    Front Neurol; 2021; 12():694329. PubMed ID: 34421799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Path to Parkinson Disease Prevention: Conclusion and Outlook.
    Berg D; Crotty GF; Keavney JL; Schwarzschild MA; Simuni T; Tanner C
    Neurology; 2022 Aug; 99(7 Suppl 1):76-83. PubMed ID: 35970586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of olfaction dysfunction with brain microstructure in prodromal Parkinson disease.
    Sanjari Moghaddam H; Dolatshahi M; Salardini E; Aarabi MH
    Neurol Sci; 2019 Feb; 40(2):283-291. PubMed ID: 30386933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in markers of prodromal Parkinson disease.
    Postuma RB; Berg D
    Nat Rev Neurol; 2016 Oct; 12(11):622-634. PubMed ID: 27786242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of prodromal motor and non-motor symptoms in the premotor phase study - 2-year follow-up data.
    Liepelt-Scarfone I; Brändle B; Yilmaz R; Gauss K; Schaeffer E; Timmers M; Wurster I; Brockmann K; Maetzler W; Van Nueten L; Streffer JR; Berg D
    Eur J Neurol; 2017 Nov; 24(11):1369-1374. PubMed ID: 28872736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.